I think that's the real reason for the delay. The trials are a smokescreen whilst they put practices into place imo. When you look at the figures, they make about $70 US in royalties on a 12 week supply sold in India. A 12 week course in the UK costs the NHS just shy of £40,000 ($61,000 US) +VAT. If they stop just 100 treatments from leaking through from India to the UK, that's well over $3,000,000 NETT profit in warehoused customers waiting to be made. I know most of us don't drink, but it's sobering (and quite nauseating) when you look at the cold, hard figures.